Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Core Insights - Beyond Air, Inc. announced the publication of a scientific article on the use of intermittent inhaled nitric oxide (iNO) for treating nontuberculous mycobacteria (NTM) lung infections, highlighting its potential as a novel anti-NTM agent [1][2][3] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors [7][8] - The company has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating hypoxic respiratory failure in neonates, and is advancing other LungFit systems in clinical trials for severe lung infections [7][11] Clinical Study Details - The LungFit GO NTM Trial was a 12-week, multi-center, open-label clinical trial involving 15 subjects with chronic refractory NTM lung disease, supported by the U.S. Cystic Fibrosis Foundation [3][4] - Subjects were treated with high doses of iNO, starting at 150 ppm and titrated to 250 ppm, with a high treatment compliance rate of over 90% and no serious adverse events reported [4][5] Efficacy and Safety Findings - Key efficacy endpoints showed meaningful improvements in quality of life, particularly in respiratory symptoms and emotional functioning, with trends indicating a reduction in microbial load [5] - The study demonstrated a favorable safety profile, with no occurrences of methemoglobinemia and no treatment-related discontinuations [4][5] Future Directions - The results from the pilot study support the need for further evaluation of iNO as a treatment for NTM infections in larger pivotal studies [2][3]